UVB-induced Treg Cells Exert Antigen-specific Suppression Through LAG-3

The goal of this clinical trial is to compare the immune cell population in blood of the participants with psoriasis/atopic dermatitis before and after UVB treatment. The main questions it aims to answer are:how immune cells in the PBMCs from blood of participants are affected by UVB treatmentwill UVB treatment expand the antigen-specific Treg cell populationwill UVB treatment enhance the suppressive function of Treg cellsParticipants giving written informed consent will donate their blood (20 ml) before UVB treatment begins. After 8 to 10-week treatment course, the participants will donate their blood (20 ml) again.Researchers will compare immune cell population changes in the PBMCs of participants before and after UVB treatment. In addition, researchers will purify Treg cells from participant blood before and after UVB treatment to test their suppressive activity by ex vivo suppression assay.

Inclusion Criteria:At least 20 years of ageAble and willing to provide written informed consentExclusion Criteria:UV exposure in the last 8 weeks before study entryPatients with contraindications for UV-treatmentHistory of cancer and primary immunodeficiencypregnant or nursing motherparticipating in another clinical trial